Downregulation of CEACAM1 has been described in prostate, colon, and breast cancer, whereas CEACAM1 upregulation correlates with disease progression in melanoma and pulmonary adenocarcinoma [6–11]. This evidence concerns the gene CEACAM1 and melanoma.